Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [911]
News [3678]
Articles [22]
Editorials [1]
Conferences [135]
elearning [0]
Editor's ESMO 2016 roundup
Prof Gordon McVie - Editor in Chief, ecancer
Editor's ESMO 2016 roundup ( Prof Gordon McVie - Editor in Chief, ecancer )
24 Oct 2016
CDK4/6 inhibitors for metastatic breast cancer
Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy
CDK4/6 inhibitors for metastatic breast cancer ( Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )
14 Oct 2016
ESMO 2016 conference highlights
Dr Bishal Gyawali - Nagoya University, Nagoya, Japan
ESMO 2016 conference highlights ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )
12 Oct 2016
Lurbinectedin in PARP resistant breast cancer
Dr Cristina Cruz - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Lurbinectedin in PARP resistant breast cancer ( Dr Cristina Cruz - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
10 Oct 2016
Treating CNS metastases from breast cancer with a peptide/paclitaxel conjugate
Prof Shou-Ching Tang - Augusta University Cancer Center, Augusta USA
Treating CNS metastases from breast cancer with a peptide/paclitaxel conjugate ( Prof Shou-Ching Tang - Augusta University Cancer Center, Augusta USA )
10 Oct 2016
Highlights of ESMO 2016
Dr Andrés Cervantes - ESMO 2016 Scientific Chair
Highlights of ESMO 2016 ( Dr Andrés Cervantes - ESMO 2016 Scientific Chair )
10 Oct 2016
Custirsen shows no survival benefit in metastatic prostate cancer
Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
Custirsen shows no survival benefit in metastatic prostate cancer ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )
10 Oct 2016
Negative trial results of custirsen for metastatic prostate cancer
Prof Karim Fizazi - Cancer Medicine at the Institut Gustave Roussy, Villejuif...
Negative trial results of custirsen for metastatic prostate cancer ( Prof Karim Fizazi - Cancer Medicine at the Institut Gustave Roussy, Villejuif, France )
10 Oct 2016
Advances for NSCLC in review
Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland
Advances for NSCLC in review ( Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland )
9 Oct 2016
Ceritinib following crizotinib relapse for ALK positive NSCLC
Dr Giorgio Scagliotti - University of Turin, Turin, Italy
Ceritinib following crizotinib relapse for ALK positive NSCLC ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )
9 Oct 2016
ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib
Dr Giorgio Scagliotti - University of Turin, Turin, Italy
ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )
9 Oct 2016
Phase I results of a novel FGFR inhibitor
Dr Markus Joerger - Kantonsspital St. Gallen, St. Gallen, Switzerland
Phase I results of a novel FGFR inhibitor ( Dr Markus Joerger - Kantonsspital St. Gallen, St. Gallen, Switzerland )
9 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation